You are here: 
text zoom : S | M | L
Printer Friendly Version
Login
Further Enquiries

Centre for Personalised Cancer Medicine
Hanson Institute Building
THE UNIVERSITY OF ADELAIDE
SA 5005
AUSTRALIA

Phone: +61 8 8222 3145
Fax: +61 8 8222 3217
Email

Publications from selected members since 2010

Prof David F Callen

  1. Parimi S, Barnes TJ, Callen DF, Prestidge CA. (2010) Mechanistic insight into cell growth, internalization, and cytotoxicity of PAMAM dendrimers. Biomacromolecules, 11:382-9. IF=4.1
  2. Tischfield MA, Baris HN, Wu C, Rudolph G, Van Maldergem L, He W, Chan W-M, Andrews C, Demer JL, Robertson RL, Mackey DA, Ruddle JB, Bird TD, Gottlob I, Pieh C, Traboulsi EI, Pomeroy SL, Hunter DG, Soul JS, Newlin A, Sabol LJ, Doherty EJ, de Uzcategui CE, De Uzcategui N, Collins ML, Sener EC, Wabbels B, Hellebrand H, Meitinger T, de Berandinis T, Magli A, Schiavi C, Pastore-Trossello M, Koc F, Wong AM, Levin AV, Geraghty MT, Descartes M, Flaherty MP, Jamieson RV, Moller HU, Meuthen I, Callen DF, Kerwin J, Lindsay S, Meindl A, Gupta ML, Jr Pellman D, and Engle EC (2010) Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell, 140:74-87. IF=31.3
  3. Callen DF, Ricchardelli C, Butler M, Stapleton A, Stahl J, Kench JG, Horsfall DJ, Tilley WD, Schulz R, Nesland JM, Neilsen PM, Kumar R, Holm R (2010) Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncol Rep 23: 1045-52, IF=1.5
  4. Sharma RK, Cheney KM, Neilsen PM, Schulz RB, Callen DF (2010) CBFA2T3-ZNF651, like CBFA2T3-ZNF652, functions as a transcriptional corepressor complex. FEBS Lett 584: 859-64, IF=3.26
  5. Lamprecht B, Walter K, Kreher S, Kumar R, Hummel M, Lenze D, Köchert K, Bouhlel MA, Richter J, Soler E, Stadhouders R, Jöhrens K, Wurster KD, Callen DF, Harte MF, Giefing M, Barlow R, Stein H, Anagnostopoulos I, Janz M, Cockerill PN, Siebert R, Dörken B, Bonifer C, Mathas S (2010) De–repression of an endogenous long terminal repeat activates the CSF1R proto–oncogene in human lymphoma. Nat Med, 16:571-9. IF=27.6
  6. Kumar R, Iachini DN, Neilsen PM, Kaplan J, Michalakas J, Anderson PH, May BK, Morris HA, Callen DF (2010) Systematic characterisation of the rat and human CYP24A1 promoter . Mol Cell Endocrinol 325:46-53. IF=3.6
  7. Pishas K, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown M, Callen DF, Neilsen PM (2011) Nutlin-3a is a potential therapeutic for Ewing Sarcoma. Clin Cancer Res 17(3):494-504. IF=6.8
  8. Neilsen PM, Pishas KI, Callen DF, and Thomas DM (2011), Targeting the p53 pathway in Ewing sarcoma, Sarcoma. 2011:746939. Epub 2010 Dec 9.
  9. Fullston T, Gabb B, Callen D, Ullmann R, Woollatt E, Bain S, Ropers HH, Cooper M, Chandler D, Carter K, Jablensky A, Kalaydjieva L, Gecz J (2011) Inherited balanced translocation t(9;17)(q33.2;q25.3) concomitant with a 16p13.1 duplication in a patient with schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2011 Jan 13. [Epub ahead of print]. IF=3.8
  10. Lim SP, Neilsen P, Kumar R, Abell A, Callen DF (2011) The application of delivery systems for DNA methyltransferase inhibitors. BioDrugs in press. IF=2.8

Prof Michael Brown

  1. Brown MP. Is HLA involved in the anti-melanoma activity of ipilimumab? Immunotherapy (Accepted 20 January 2011).
  2. Lousberg EL, Diener KR, Fraser CK, Phipps S, Foster PS, Chen W, Uematsu S, Akira S, Robertson SA, Brown MP, Hayball JD. Innate immune recognition of recombinant fowlpox virus by TLR7 and TLR9 does not contribute to MyD88-mediated and IL-18-dependent antigen-specific adaptive immune responses. J Virol (Accepted 11 January 2011).
  3. Kirkwood JM, Gonzalez R, Reintgen D, Clingan PR, McWilliams RR, de Alwis DP, Zimmermann A, Brown MP, Ilaria RL, Millward MJ. A Phase II Study of Tasisulam (LY573636) as Second-Line Treatment for Patients with Unresectable or Metastatic Melanoma. Cancer (Accepted 11 January 2011).
  4. Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, López JA, Lakhani SR, Brown MP, Khanna KK. Breast cancer stem cells: treatment resistance and therapeutic opportunities. in Carcinogenesis (Accepted 05 January 2011).
  5. Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF, Neilsen PM. Clin Cancer Res. 2010 Nov 23. [Epub ahead of print] Nutlin-3a is a potential therapeutic for Ewing Sarcoma. http://www.ncbi.nlm.nih.gov/pubmed/21098696 (2009 JIF: 6.747).

Assoc Prof Richard D’Andrea

  1. Kok CH, Brown AL, Ekert PG, D'Andrea RJ. (2010) Gene expression analysis reveals HOX gene upregulation in trisomy 8 AML. Leukemia, [Epub ahead of print] (IF – 8.296)
  2. Perugini M, Brown AL, Salerno DG, Booker GW, Stojkoski C, Hercus TR, Lopez AF, Hibbs ML, Gonda TJ, D'Andrea RJ. (2010) Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit. Blood , 115(16):3346-53. (IF – 10.555)
  3. Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, Guthridge MA, Lopez AF, D'Andrea RJ, To LB, Melo JV, Kumar S, Hughes TP. (2010) Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia, 24(4):771-8. (IF – 8.296)
  4. Sadlon TS, Wilkinson BG, Pederson S, Brown CY, Bresatz S, Gargett T, Melville E, Peng K, D’Andrea R, Glonek G, Goodall GJ, Zola H, Shannon MF, Barry SC. (2010) Genome wide identification of human FOXP3 target genes in natural regulatory T cells. Journal of Immunology, 185:1071 -1081. (IF – 5.646)
  5. AF Lopez, TR Hercus, P Ekert, DR Littler, M Guthridge, D Thomas, HS Ramshaw, F Stomski, M Perugini, RJ D’Andrea, M Grimbaldeston, and MW Parker (2010) “Molecular basis of Cytokine Receptor Activation” IUBMB Life Journal, 62(7):509-518. (IF – 3.578)
  6. M. Perugini, H. Lee, S. McRae, R.J. D’Andrea. (2010) Pharmacotherapy of Chronic Immune Thrombocytopenia Purpura (ITP) with Romiplostim. Clinical Medicine Reviews in Therapeutics, 2:1-7.
  7. V.P.S. Rawat, N. Arseni, F. Ahmed, M.A. Mulaw, S. Thoene, B. Heilmeier, T. Sadlon, R.J. D’Andrea, W. Hiddemann, S.K. Bohlander, C. Buske and M. Feuring-Buske. (2010) The Vent-like homeobox gene VENTX promotes human myeloid development in vitro and in vivo and is highly expressed in acute myeloid leukemia. Proc. Nat. Acad. Sci. USA, 107(39) 16946-16951. (IF – 9.432)
  8. C Butcher, P Neufing, L Eriksson, C Carmichael, E Wilkins, J Melo, I Lewis, P Bardy, H Scott, R D’Andrea. (2011) RUNX1 mutations are rare in chronic phase polycythemia vera. British Journal of Haematology, epub ahead of print DOI: 10.1111/j.1365-2141.2011.08589.x (IF – 4.597)

Prof Dorothy M K Keefe

  1. Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat. Al-Dasooqui N, Bowen JM, Gibson R J, Logan R M, Stringer A M, Keefe D M. Int J Exp Pathol. 2011 (in press)
  2. Patient-Reported outcomes in supportive oncology. Bateman E & Keefe, DM. Seminars in Oncology. 2011 (in press)
  3. Non Cardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review. Keefe DM, Bowen JM, Gibson RJ, Tan TH, Okera M, Stringer AM, The Oncologist. 2011 (in press)
  4. Selection of Housekeeping Genes for Gene Expression Studies in a Rat Model of Irinotecan-Induced Mucositis. Al-Dasooqi N, Bowen JM, Gibson R J, Logan R M, Stringer A M, Keefe D M. Chemotherapy. 2011; 57(1) 43-53.
  5. Matrix Metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Al-Dasooqui, N., Gibson, R.J., Bowen, J.M., Logan, R.M., Stringer, A.M., Keefe D.M. Experimental Biology and Medicine 2010; 235:1244-1256.
  6. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Ong, ZY, Gibson RJ, Bowen JM, Stringer AM, Darby JM, Logan RM, Yeoh ASJ, Keefe DMK. Radiation Oncology 2010; 5:22
  7. Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract. Bowen J, Tsykin A, Stringer A, Logan R, Gibson R, Keefe D. Toxicology. 269(1):1-12, 2010

Prof Tanya Monro

  1. M.R. Henderson, B.C. Gibson, H. Ebendorff-Heidepriem, K. Kuan, S. Afshar V., J.O. Orwa, I. Aharonovich, S. Tomljenovic-Hanic, A.D. Greentree, S. Prawer, T.M. Monro, “Diamond in tellurite glass: A new medium for quantum information”, Advanced Materials, April 2011 (early online access)
  2. S. Atakaramians, S. Afshar V., M. Nagel, H.K. Rasmussen, O. Bang, T.M. Monro, D. Abbott, “Direct probing of evanescent field for characterization of porous THz fibers”, Applied Physics Letters 98, (12), April 2011
  3. D.G. Lancaster, S. Gross, H. Ebendorff-Heidepriem, K. Kuan, T.M. Monro, M. Ams, A. Fuerbach, M.J. Withford, “50% internal efficiency fs direct-written Tm3+: ZBLAN waveguide laser”, Optics Letters 36, (9), 1587-1589, April 2011
  4. T. Palmisano, F. Prudenzano, S.C. Warren-Smith, T.M. Monro, “Design of exposed-core fiber for methadone monitoring in biological fluids”, Journal of Non-Crystalline Solids 357, (8-9), 2000-2004, April 2011
  5. S.C. Warren-Smith, S. Heng, H. Ebendorff-Heidepriem, A.D. Abell, T.M. Monro, “Fluorescence-Based Aluminum Ion Sensing using a Surface Functionalized Microstructured Optical Fiber”, Langmuir 27, (9), 5680–5685, April 2011
  6. E.P. Schartner, H. Ebendorff-Heidepriem, S.C. Warren-Smith, R.T White, T.M. Monro, “Driving down the Detection Limit in Microstructured Fiber-Based Chemical Dip Sensors”, Sensors 11, (3), 2961-2971, March 2011
  7. J. Boehm, A. François, H. Ebendorff-Heidepriem, T.M. Monro, “Chemical Deposition of Silver for the Fabrication of Surface Plasmon Microstructured Optical Fibre Sensors”, Plasmonics 6, (1), 133-136, March 2011
  8. Francois, J. Boehm, S.Y. Oh, T. Kok, T.M. Monro, “Collection mode surface plasmon fiber sensors: a new biosensing platform" Biosensors and Bioelectronics 26, 3154-3159, February 2011
  9. Y. Ruan, S. Afshar V., T.M. Monro, “Light Enhancement within Nanoholes in High Index Contrast Nanowires”, IEEE Photonics Journal 3, (1), 130-139, February 2011
  10. M. Lohe, W.Q. Zhang, T.M. Monro, S. Afshar V., “Nonlinear Polarization Bistability in Optical Nanowires”, Optics Letters 36 (4), 558-590, February 2011
  11. T.M. Monro, S.C. Warren-Smith, E.P. Schartner, A. François, S. Heng, H. Ebendorff-Heidepriem, S. Afshar V., “Sensing with suspended-core optical fibers”, Optical Fibre Technology 16 (6), 343-356, December 2010
  12. Y. Ruan, H. Ebendorff-Heidepriem, S. Afshar V., T.M. Monro, “Light confinement within nanoholes in nanostructured optical fibers”, Optics Express 18 (25) 26018-26026, November 2010
  13. C. Kalnins, H. Ebendorff-Heidepriem, N. Spooner, T.M. Monro, “Optically stimulated luminescence in fluoride-phosphate glass for radiation dosimetry”, Journal of the American Ceramic Society, 94 (2), 474–477, November 2010 (early online access)
  14. D. Buccoliero, H. Steffensen, O. Bang, H. Ebendorff-Heidepriem, T.M. Monro, “Thulium pumped high power supercontinuum in loss-determined optimum lengths of tellurite photonic crystal fiber”, Applied Physics Letters 97, 061106, August 2010
  15. W.Q. Zhang, J.E. Sharping, R.T. White, T.M. Monro, S. Afshar V., “Design and optimization of fiber optical parametric oscillators for femtosecond pulse generation”, Optics Express 18 (16), 17294-17305, July 2010
  16. S.C. Warren-Smith, E. Sinchenko, P.R Stoddart, T.M. Monro, “Distributed Fluorescence Sensing Using Exposed-Core Microstructured Optical Fiber”, Photonics Technology Letters 22 (18), 1385 - 1387, July 2010
  17. S.C. Warren-Smith, S. Afshar V., T.M. Monro, “Fluorescence-based sensing with optical nanowires: a generalized model and experimental validation”, Optics Express 18 (9), 9474-9485, April 2010

Prof Paul Rolan

  1. Cathcart S, Winefield AH, Lushington K, Rolan P. Noxious Inhibition of Temporal Summation is Impaired in Chronic Tension-Type Headache. Headache 2010; 50: 403-12
  2. Cathcart S, Petkov J, Winefield AH, Lushington K, Rolan P. Central mechanisms of stress-induced headache. Cephalalgia 2010 30:285-95.
  3. Grace PM, Stanford T, Gentgall M, Rolan PE. Utility of saccadic eye movement analysis as an objective biomarker to detect the sedative interaction between opioids and sleep deprivation in opioid-naïve and opioid-tolerant populations. Journal of Psychopharmacology 2010 24:1631-1640.
  4. Grace PM, Hutchinson MR, Manayis J, Somogyi AA, Rolan PE. A novel animal model of graded neuropathic pain: Utility to investigate mechanisms of population heterogeneity. J Neurosci Methods 2010 193:47-53.
  5. Grace PM, Hutchinson MR, Bishop A, Somogyi AA, Mayrhofer G, Rolan PE. Adoptive transfer of peripheral immune cells potentiates allodynia in a graded chronic constriction injury model of neuropathic pain. Brain, Behavior, and Immunity 2011 25(3) 503-13
  6. Rolan P, Sun H, MacLeod C, Bracken K, Evans TG. Pharmacokinetics and unexpected safety issues of a novel oral peptide deformylase inhibitor, LBM415. Clinical Pharmacology and Therapeutics, in press.
  7. Grace PM, Rolan PE and Hutchinson MR (2011). Peripheral immune contributions to the maintenance of central glial activation underlying neuropathic pain. Brain Behav Immun. In press
  8. Rolan PE. The Placebo Response Is Part of Good Medicine. Clin Pharm Ther 2011; 89:4, 485.

Prof Andrew A Somogyi

  1. Somogyi AA and Hardy J. Role of pharmacogenomics in pain therapy: focus on opioids. Cancer Forum 34, 74-77, 2010
  2. Upton RN, Somogyi AA, Martinez AM, Colvill J, Grant C. Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep. British Journal of Anaesthesia 105, 798-809, 2010
  3. Gordon AL, Lopatko OV, Somogyi AA, Foster DJ, White AM. (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. British Journal of Clinical Pharmacology 70, 895-902, 2010.
  4. Grace PM, Hutchinson MR, Manavis J, Somogyi AA, Rolan PE. A novel animal model of graded neuropathic pain: utility to investigate mechanisms of population heterogeneity. Journal of Neuroscience Methods 193, 47-53, 2010.
  5. Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, Miners JO. In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. Journal of Pharmacology and Experimental Therapeutics 334, 609-618, 2010.
  6. Hutchinson MR, Lewis SS, Coats BD, Rezvani N, Zhang Y, Wieseler JL, Somogyi AA, Yin H, Maier SF, Rice KC, Watkins LR. Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience 167, 880-893, 2010
  7. Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, Laurent-Puig P, Molina MA, Niemi M, Schwab M, Somogyi AA, Thervet E, Maitland-van der Zee AH, van Kullenburg AB, van Schaik RH, Verstuyft C, Wadelius M, Daly AK. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 12, 113-124, 2011.
  8. Hay JL, La Vincente SF, Somogyi AA, Chapleo CB, White JM. Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects. European Journal of Pain 15, 293-298, 2011.

Prof Luen Bik To

  1. Martin SK, Diamond P, Williams SA, To LB, Peet DJ, Fujii N, Gronthos S, Harris AL, Zannettino ACW. The HIF-2 transcription factor is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica 2010; 95: 776 - 784. Cit: 1
  2. Worthley DL, Ruszkiewicz A, Davies R, Moore S, Nivison-Smith I, To LB, Browett P, Western R, Durrant S, So J, Young GP, Mullighan CG, Bardy PG, Michael MZ . Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow derived cells following allogeneic stem cell transplantation. Stem Cells 2009;27(6)1463-1468 Cit: 6; IF: 7.747
  3. Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, Guthridge MA, Lopez AF, D’Andrea RJ, To LB, Melo JV, Kumar S, Hughes TP. Blocking cytokine signalling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 2010; 24(4):771-778. Cit: 2; IF: 8.296
  4. Hodge G, Scott J, Osborn M, To LB, Zola H, Hodge S, Revesz T. Increased T regulatory cells and decreased Th1 pro-inflammatory cytokines correlate with culture-positive infection in febrile neutropenia childhood oncology patients. Cytokine 2011; 53(3):286-288. Cit: 0; IF: 3.123

Assoc Prof Deborah White

  1. Engler JR, Frede A, Saunders VA, Zannettino ACW, Hughes TP, White DL (2010) CML CD34+ cells have Reduced Uptake of Imatinib due to Low OCT-1 Activity. Leukemia 24, 765-770 IF= 8.634. Cit = 8
  2. Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, Guthridge MA, Lopez AF, D’Andrea RJ, To LB, Melo JV, Kumar S, Hughes TP (2010) Blocking Cytokine Signaling Along With Intense Bcr-Abl Kinase Inhibition Induces Apoptosis In Primary CML Progenitors. Leukemia 24, 771-778 IF= 8.634 Cit = 2
  3. Eadie L, Hughes TP, White DL (2010) Nilotinib does not significantly reduce imatinib OCT-1 Activity in cell lines and primary patient cells Leukemia 24, 855-857 IF= 8.634 Cit = 2
  4. White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, Saunders VA, Manley PW, TP Hughes (2010) The functional activity of the OCT-1 protein is predictive of long term outcome in CP-CML patients treated with Imatinib. J Clin Oncol 28: 2761-2767 IF=17.157 Cit = 17
  5. Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino ACW (2010) Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients? J Clin Endocrinol Metab 95:3763-7 IF=6.02
  6. Hiwase DK, White D, Zrim S, Saunders V, Melo JV, Hughes TP (2010) Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia 24:658-60 IF= 8.634. Cit = 5
  7. Engler JR, Frede A, Saunders V, Zannettino A, White DL, Hughes TP (2010) The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. Blood 116: 2776-2778. IF=10.896 Cit = 3
  8. Yeung DT, White DL (2011) Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all? Leuk Lymphoma 52:165-7. IF- 2.7
  9. Engler JR, Zannettino AC, Bailey CG, Rasko JE, Hughes TP, White DL (2011) OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica 96:213-20
  10. Engler JR, Hughes TP, White DL (2011) OCT-1 as a determinant of response to antileukemic treatment. Clin Pharmacol Ther. 89:608-11
  11. Hiwase DK, Yeung DT, White DL (2011) Optimizing the selection of Kinase Inhibitors for CML patients. Expert Review of Hematology, Accepted for Publication Feb 2011.

Prof Andrew Zannettino

  1. Gronthos S, Zannettino AC. Methods for the purification and characterization of human adipose-derived stem cells. Methods Mol Biol. 2011; 702:109-20.
  2. Martin SK, Diamond P, Gronthos S, Peet D, Zannettino AC, The emerging role of Hypoxia, HIF-1 and HIF-2 in Multiple Myeloma, Review. 2011. Accepted for publication.
  3. Dharmapatni AA, Smith MD, Crotti TN, Holding CA, Vincent C, Weedon HM, Zannettino AC, Zheng TS, Findlay DM, Atkins GJ, Haynes DR. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther. 2011 13(2):R51. [Epub ahead of print]
  4. Vandyke K, Fitter S, Zannettino ACW. The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer Journal. 2011 (accepted)
  5. Goldschlager T, Ghosh P, Zannettino A, Williamson M, Rosenfeld JV, Itescu S, Jenkin G. A Comparison of Mesenchymal Precursor cells with Amnion Epithelial cells for Enhancing Cervical Interbody Fusion in an Ovine Model. Neurosurgery. 2011 Jan 20. [Epub ahead of print]
  6. Field JR, McGee M, Stanley R, Ruthenbeck G, Papadimitrakis T, Zannettino A, Gronthos S, Itescu S. The efficacy of allogeneic mesenchymal precursor cells for the repair of an ovine tibial segmental defect. Vet Comp Orthop Traumatol. 2011;24:113-21
  7. See F, Seki T, Psaltis PJ, Sondermeijer HP, Gronthos S, Zannettino AC, Govaert KM, Schuster MD, Kurlansky PA, Kelly DJ, Krum H, Itescu S. Therapeutic Effects of Human STRO-3-Selected Mesenchymal Precursor Cells and their Soluble Factors in Experimental Myocardial Ischemia. J Cell Mol Med. 2010 Dec 14. [Epub ahead of print].
  8. Arthur A, Zannettino A, Panagopoulos R, Koblar SA, Sims NA, Stylianou C, Matsuo K, Gronthos S. EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. Bone. 2011 48(3):533-42
  9. Engler JR, Zannettino AC, Bailey CG, Rasko JE, Hughes TP, White DL. OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica. 2011 96(2):213-20.
  10. Psaltis PJ, Carbone A, Nelson AJ, Lau DH, Jantzen T, Manavis J, Williams K, Itescu S, Sanders P, Gronthos S, Zannettino AC, Worthley SG. Reparative effects of allogeneic mesenchymal precursor cells delivered transendocardially in experimental nonischemic cardiomyopathy. JACC Cardiovasc Interv. 2010; 3(9):974-83.
  11. Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V, Diamond P, Findlay DM, Zannettino AC, Evdokiou A. Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. J Bone Miner Res. 2011; 26(3):630-43.
  12. McCarty RC, Xian CJ, Gronthos S, Zannettino AC, Foster BK. Application of autologous bone marrow derived mesenchymal stem cells to an ovine model of growth plate cartilage injury. Open Orthop J. 2010;4:204-10.
  13. Zannettino AC, Paton S, Itescu S, Gronthos S. Comparative assessment of the osteoconductive properties of different biomaterials in vivo seeded with human or ovine mesenchymal stem/stromal cells. Tissue Eng Part A. 2010;16(12):3579-87.
  14. Psaltis PJ, Carbone A, Leong DP, Lau DH, Nelson AJ, Kuchel T, Jantzen T, Manavis J, Williams K, Sanders P, Gronthos S, Zannettino AC, Worthley SG. Assessment of myocardial fibrosis by endoventricular electromechanical mapping in experimental nonischemic cardiomyopathy. Int J Cardiovasc Imaging. 2011; 27(1):25-37.
  15. Goldschlager T, Jenkin G, Ghosh P, Zannettino A, Rosenfeld JV. Potential applications for using stem cells in spine surgery. Curr Stem Cell Res Ther. 2010;5(4): 345-55
  16. Goldschlager T, Ghosh P, Zannettino A, Gronthos S, Rosenfeld JV, Itescu S, Jenkin G. Cervical motion preservation using mesenchymal progenitor cells and pentosan polysulfate, a novel chondrogenic agent: preliminary study in an ovine model. Neurosurg Focus. 2010; 28(6):E4.
  17. Martin SK, Fitter S, Bong LF, Drew JJ, Gronthos S, Shepherd PR, Zannettino AC. NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J Bone Miner Res. 2010; 25(10):2126-37.
  18. Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab. 2010; 95(8):3763-7.
  19. McCarty RC, Xian CJ, Gronthos S, Zannettino ACW, Foster BK. Application of Autologous Bone Marrow Derived Mesenchymal Stem Cells to an Ovine Model of Growth Plate Cartilage Injury. The Open Orthopaedics Journal, 2010; 4, 220-226.
  20. Martin SK, Fitter S, Bong LF, Drew JJ, Gronthos S, Shepherd PR, Zannettino AC. NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J Bone Miner Res. 2010; 25(10):2126-37.
  21. Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC. Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients? J Clin Endocrinol Metab. 2010; 95(8):3763-7.
  22. Psaltis PJ, Paton S, See F, Arthur A, Martin S, Itescu S, Worthley SG, Gronthos S, Zannettino AC. Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. J Cell Physiol. 2010; 223:530-40.
  23. Winkler IG, Barbier V, Wadley R, Zannettino A, Williams S, Levesque JP. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: Serially reconstituting hematopoietic stem cells reside in distinct non-perfused niches. Blood. 2010; 116(3):375-85.
  24. Williams SA, Martin SK, Vincent C, Gronthos S, Zheng T, Atkins GJ, Zannettino AC. Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. Br J Haematol. 2010; 150(3):373-6.
  25. Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia. 2010; 24(4):765-70.
  26. Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG, Sims NA, Zannettino AC. The tyrosine kinase inhibitor dasatinib dysregulates bone remodelling through inhibition of osteoclasts in vivo. J Bone Miner Res. 2010; 25(8):1759-70
  27. Castrechini N, Murthi P, Gude NM, Erwich JJ, Gronthos S, Zannettino A, Brennecke SP, Kalionis B. Mesenchymal stem cells in human placental chorionic villi reside in a vascular Niche. Placenta. 2010; 31(3):203-12.
  28. Ghosh P, Wu J, Shimmon S, Zannettino AC, Gronthos S, Itescu S. Pentosan polysulfate promotes proliferation and chondrogenic differentiation of adult human bone marrow-derived mesenchymal precursor cells. Arthritis Res Ther. 2010 Feb 18;12(1):R28.
  29. Menicanin D, Bartold PM, Zannettino AC, Gronthos S. Identification of a Common Gene Expression Signature Associated with Immature Clonal Mesenchymal Cell Populations derived from Bone Marrow and Dental Tissues. Stem Cells Dev. 2010 Oct;19(10):1501-10.
  30. Psaltis PJ, Zannettino AC, Gronthos S, Worthley SG. Intramyocardial navigation and mapping for stem cell delivery. J Cardiovasc Transl Res. 2010; 3(2):135-46.